Overview

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Status:
Recruiting
Trial end date:
2022-11-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether combining the study drugs rucaparib and nivolumab may be an effective treatment for advanced and/or metastatic LMS, and whether the study treatment works as well as the standard chemotherapy for this type of cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Bristol-Myers Squibb
Clovis Oncology, Inc.
Treatments:
Nivolumab
Rucaparib